| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Regulation FD Disclosure
NASDAQ: HBIO Harvard Bioscience Investor Overview November 202 6 |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Harvard Bioscience Announces Third Quarter 2026 Financial Results |
| 11 Aug 2026 |
8-K: Regulation FD Disclosure
NASDAQ: HBIO Harvard Bioscience Investor Overview August 202 6 |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Harvard Bioscience Announces Second Quarter 2026 Financial Results |
| 02 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of the Harvard Bioscience, Inc. Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Harvard Bioscience, Inc. (the “Company”) and certain of its subsidiaries with opportunities to purchase shares of t... |
| 12 May 2026 |
8-K: Regulation FD Disclosure
Forward - Looking Statements & Non - GAAP Financial Information Forward Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Harvard Bioscience Announces First Quarter 2026 Financial Results |
| 17 Mar 2026 |
8-K: Regulation FD Disclosure
NASDAQ: HBIO Harvard Bioscience Investor Overview March 202 6 |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results |
| 10 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 6th day of March, 2026 (the “Effective Date”), between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and Mark Frost (“Executive”... |
| 06 Mar 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure +1 more
Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 |
| 10 Feb 2026 |
8-K: Results of Operations and Financial Condition
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas |
| 29 Jan 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth |
| 20 Jan 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Article I, Section 5 of the Amended and Restated By-laws of Harvard Bioscience, Inc., is hereby deleted in its entirety and replaced with the following: |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
HBio Confidential 1 NASDAQ: HBIO HBIO Investor Overview January 202 6 |
| 17 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of December 17, 2025 (the “Closing Date”) is entered into among Harvard Bioscience, Inc., a Delaware... |
| 05 Dec 2025 |
8-K: Other Events
The Company is engaged in ongoing discussions relating to its existing credit agreement, dated December 22, 2020, as amended, with Citizens Bank, N.A., Wells Fargo Bank, N.A., and First-Citizens Bank & Trust Company (the “Credit Agreemen... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Harvard Bioscience Announces Third Quarter 2025 Financial Results |
| 03 Oct 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On October 2, 2025, Harvard Bioscience, Inc., (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been... |
| 09 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors |
Loading...